[go: up one dir, main page]

BRPI0810951A2 - Proteína l1 hpv6, polinucleotídeo, vetor, célula, composição, partícula semelhante ao vírus (vlp) hpv6, método para produzir uma proteína l1 do hpv, vacina para prevenção de condiloma acuminado ou de infecções porhpv, uso da proteína, método para prevenção de condiloma acuminado ou infecções por hpv, método pra obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv - Google Patents

Proteína l1 hpv6, polinucleotídeo, vetor, célula, composição, partícula semelhante ao vírus (vlp) hpv6, método para produzir uma proteína l1 do hpv, vacina para prevenção de condiloma acuminado ou de infecções porhpv, uso da proteína, método para prevenção de condiloma acuminado ou infecções por hpv, método pra obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv

Info

Publication number
BRPI0810951A2
BRPI0810951A2 BRPI0810951-6A BRPI0810951A BRPI0810951A2 BR PI0810951 A2 BRPI0810951 A2 BR PI0810951A2 BR PI0810951 A BRPI0810951 A BR PI0810951A BR PI0810951 A2 BRPI0810951 A2 BR PI0810951A2
Authority
BR
Brazil
Prior art keywords
protein
hpv6
prevention
condyloma
acuminate
Prior art date
Application number
BRPI0810951-6A
Other languages
English (en)
Inventor
Shaowei Li
Huirong Pan
Bo Liu
Jun Zhang
Ji Miao
Ningshao Xia
Original Assignee
Univ Xiamen
Beijing Wantai Biological Pharmacy Entpr Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Xiamen, Beijing Wantai Biological Pharmacy Entpr Co Ltd filed Critical Univ Xiamen
Publication of BRPI0810951A2 publication Critical patent/BRPI0810951A2/pt
Publication of BRPI0810951B1 publication Critical patent/BRPI0810951B1/pt
Publication of BRPI0810951B8 publication Critical patent/BRPI0810951B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2796/00—Viruses not covered by groups C12N2710/00 - C12N2795/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0810951A 2007-05-29 2008-05-29 proteína l1 do hpv6, polinucleotídeo, vetor, célula, partícula semelhante ao vírus (vlp) hpv6, método para produzir a proteína hpv6 l1 truncada, vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína hpv6 l1 truncada, método para prevenção de condiloma acuminado ou infecções por hpv, método para obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv BRPI0810951B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200710105764 2007-05-29
CN200710105764.7 2007-05-29
PCT/CN2008/001050 WO2008145021A1 (fr) 2007-05-29 2008-05-29 Protéine l1 tronquée du papillomavirus humain de type 6

Publications (3)

Publication Number Publication Date
BRPI0810951A2 true BRPI0810951A2 (pt) 2015-07-21
BRPI0810951B1 BRPI0810951B1 (pt) 2020-10-06
BRPI0810951B8 BRPI0810951B8 (pt) 2021-05-25

Family

ID=40074567

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810951A BRPI0810951B8 (pt) 2007-05-29 2008-05-29 proteína l1 do hpv6, polinucleotídeo, vetor, célula, partícula semelhante ao vírus (vlp) hpv6, método para produzir a proteína hpv6 l1 truncada, vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína hpv6 l1 truncada, método para prevenção de condiloma acuminado ou infecções por hpv, método para obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv

Country Status (6)

Country Link
US (2) US8748127B2 (pt)
EP (1) EP2154149B1 (pt)
CN (1) CN101343315B (pt)
BR (1) BRPI0810951B8 (pt)
DK (1) DK2154149T3 (pt)
WO (1) WO2008145021A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499591B2 (en) 2010-07-02 2016-11-22 Xiamen University Truncated L1 protein of human papillomavirus type 52
CN102229660B (zh) 2011-05-25 2015-04-22 厦门大学 截短的人乳头瘤病毒33型l1蛋白
CN105177025B (zh) * 2013-12-03 2022-11-01 北京康乐卫士生物技术股份有限公司 18型重组人乳头瘤病毒病毒样颗粒及其制备方法
EP3364982A4 (en) * 2015-10-22 2019-04-17 ModernaTX, Inc. VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES
WO2017092711A1 (zh) 2015-12-04 2017-06-08 厦门大学 一种人乳头瘤病毒11型l1蛋白的突变体
CN106831960B (zh) * 2015-12-04 2019-11-05 厦门大学 一种人乳头瘤病毒6型l1蛋白的突变体
US11771754B2 (en) 2018-06-04 2023-10-03 Xiamen University Mutant of L1 protein of human papillomavirus type 18
JP2022518515A (ja) * 2019-01-25 2022-03-15 プソマーゲン， インコーポレイテッド 抗体－ｄｎａ複合体及びｈｐｖの検出並びに治療
EP4001298B1 (en) 2019-07-19 2025-03-05 Sinocelltech Ltd Polyvalent immunogenicity composition for human papillomavirus
CN114539364B (zh) * 2020-11-26 2023-10-20 中国医学科学院基础医学研究所 一种c端改造的人乳头瘤病毒6型l1蛋白及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3110561A1 (de) * 1981-03-18 1982-11-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Chemorekrutine der leukozyten und des entszuendungsgewebes: eine neue klasse natuerlicher leukopoetine zurselektiven chemorekrutierung von leukozyten aus dem knochenmark in den blutstrom (leukozytose- und linskverschiebungsreaktion)
FR2672895B1 (fr) * 1991-02-15 1995-05-12 Transgene Sa Procede de purification d'une proteine fortement glycosylee.
EP0688227B1 (en) 1993-03-09 2005-05-25 The University Of Rochester Production of human papillomavirus capsid protein and virus-like particles
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
AU4270196A (en) * 1994-10-07 1996-05-02 Lutz Gissmann Papilloma virus-like particles, fusion proteins and process for producing the same
US7351533B2 (en) * 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
US7182947B2 (en) * 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US20020193565A1 (en) * 1998-03-27 2002-12-19 Stanley Margaret Anne Antigen preparation and use
ES2262333T3 (es) * 1998-08-14 2006-11-16 MERCK & CO., INC. Procedimiento para purificar particulas similares a virus de papilomavirus humano.
AU3730600A (en) * 1999-03-18 2000-10-04 Xiaojiang Chen Compositions preparations and uses of human papillomavirus l1 protein
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
CN1293093C (zh) * 2002-08-30 2007-01-03 马润林 乳头瘤病毒衣壳蛋白的原核制备和应用
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
CN101153280B (zh) 2006-09-29 2015-08-19 厦门大学 从原核生物中纯化人乳头瘤病毒晚期蛋白l1的方法
GB0624227D0 (en) * 2006-12-05 2007-01-10 Common Services Agency Protein purification
CA2679720A1 (en) * 2007-03-09 2008-09-18 Merck & Co., Inc. Papillomavirus vaccine compositions
CN101570571B (zh) * 2007-04-29 2012-07-11 北京万泰生物药业股份有限公司 截短的人乳头瘤病毒18型l1蛋白
CN101293918B (zh) * 2007-04-29 2013-03-27 北京万泰生物药业股份有限公司 截短的人乳头瘤病毒16型l1蛋白
BRPI0810959B1 (pt) * 2007-05-29 2021-06-29 Xiamen Innovax Biotech Co., Ltd. Proteína l1 do hpv11, polinucleotídeo, vetor, célula, composição, partícula do tipo vírus (vlp) hpv11, método para produzir uma proteína l1 do hpv, vacina para prevenção de condiloma acuminado ou de infecções por hpv e método para produzir uma vacina para prevenção de condiloma acuminado ou infecções por hpv

Also Published As

Publication number Publication date
CN101343315A (zh) 2009-01-14
BRPI0810951B8 (pt) 2021-05-25
US9745351B2 (en) 2017-08-29
EP2154149B1 (en) 2019-07-10
US8748127B2 (en) 2014-06-10
DK2154149T3 (da) 2019-10-14
WO2008145021A1 (fr) 2008-12-04
US20140288283A1 (en) 2014-09-25
HK1124343A1 (en) 2009-07-10
US20100255021A1 (en) 2010-10-07
CN101343315B (zh) 2012-06-13
EP2154149A1 (en) 2010-02-17
EP2154149A4 (en) 2011-04-06
BRPI0810951B1 (pt) 2020-10-06

Similar Documents

Publication Publication Date Title
BRPI0810951A2 (pt) Proteína l1 hpv6, polinucleotídeo, vetor, célula, composição, partícula semelhante ao vírus (vlp) hpv6, método para produzir uma proteína l1 do hpv, vacina para prevenção de condiloma acuminado ou de infecções porhpv, uso da proteína, método para prevenção de condiloma acuminado ou infecções por hpv, método pra obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv
BRPI0810959A2 (pt) "proteína l1 do hpv11, polinucleotídeo, vetor, célula, composição, partícular semelhante ao vírus (vlp) hp11, método para produzir uma proteína l1 do hpv,vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína método para prevenção de condiloma acuminado ou infecções por hpv e método para prevenção de condiloma acuminado ou infecções por hpv.
BRPI0915896A2 (pt) ácido nucleico, método para produzir partículas similares ao vírus influenza (vlps) em uma planta, as ditas partículas similares ao vírus (vlp), uso das mesmas e composição
WO2007130330A3 (en) Polyvalent influenza virus-like particle (vlp) compositions
WO2007130327A3 (en) Influenza virus-like particle (vlp) compositions
EP2536428A4 (en) UNIVERSAL INFLUENZA VACCINES WITH VIRUSIC PARTICLES
PT2121011E (pt) Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
WO2010001409A3 (en) Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
BRPI0816330A2 (pt) Composição de polipeptídeo, método para produzir composição de polipeptídeo, construção de polipeptídeo, método para produzir uma construção de polipeptídeo, construção de ácido nucleico, medicamento ou composição de vacina, método para produzir um medicamento ou composição de vacina, e uso da composição de polipeptídeo, de uma construção de polipeptídeo, de uma construção de ácido nucléico ou de um medicamento ou de composição de vacina
WO2013006569A3 (en) Herpes virus vaccine and methods of use
WO2017192418A8 (en) Therapeutic hpv vaccine combinations
ZA201004337B (en) Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing the same
HUS1500059I1 (hu) A HPV16 és HPV18 és a HPV 31, 45 vagy 52 közül legalább egy másik HPV típus elleni vakcina
WO2013055326A3 (en) Vaccines for human papilloma virus and methods for using the same
BRPI1007584A2 (pt) vacina de sarampo-malária combinada, vetor de vírus de vacina de sarampo, hospedeiro e composição de vacina de sarampo-malária combinada
BR112013000996A2 (pt) proteína l1 hpv58 truncada ou variante da mesma, ácido nucleíco isolado, vetor, célula hospedeira, partícula do tipo viral hpv58, composição, composição farmacêutica ou vacina, método para obter uma proteína l1 hpv58 truncada, método para preparar a partícula do tipo viral hpv58, método para preparar uma vacina, método para prevenir a infecção hpv ou uma doença causada por infecção hpv, e uso da proteína l1 hpv58 truncada ou variante da mesma
HK1220736A1 (zh) 尿液中的hpv檢測
WO2014008475A3 (en) Compositions and methods related to viral vaccines
MX2014000522A (es) Composicion y metodo para tratar virus del papiloma humano (vph).
HK1125388A (en) Hpv antigens, vaccine compositions, and related methods
HK1196785A (en) Composition and method for treating hpv
HK40127522A (en) Making influenza virus vaccines without using eggs
WO2006114273A3 (en) Vaccine
HK1155480A (en) Influenza virus-like particles (vlps) comprising hemagglutinin

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: XIAMEN UNIVERSITY (CN) ; XIAMEN INNOVAX BIOTECH CO., LTD. (CN)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/05/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF